CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA (nogapendekin alfa inbakicept) ...
This study presents a comprehensive investigation into the prognostic significance of CCCRGs in HCC. Notably, our research provides the first mechanistic evidence that CENPI promotes HCC malignant ...
In a new paper published in Cancer Research, researchers at MUSC Hollings Cancer Center have shown that targeting a protein called TACC3 (transforming acidic coiled-coil containing protein 3) can ...
Figure 6. Senescent heterogeneity model based on DNA content. Compared to G1-arrested cells, G2-arrested senescent cells express higher levels of senescence-associated markers, secrete more IL-6, and ...
Every day, our bodies perform around 330 billion cell divisions to keep us alive and functioning. These divisions rely on the cell cycle, which has been in place since the earliest bacteria. The ...
Assessing risk factors for the development of pulmonary hypertension in patients with myeloproliferative neoplasms: A meta-analysis and meta-regression. Validation of the International Consensus ...
Checkpoint Therapeutics, Inc. announced that the U.S. FDA approved its drug UNLOXCYT™ (cosibelimab-ipdl) in December 2024, making it the first and only anti-PD-L1 treatment for adults with advanced ...
1 Department of Gynecology and Obstetrics, Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing, China. 2 Department of Gynecology and Oncology, Beijing Obstetrics and Gynecology ...
Study: Characterizing the evolutionary dynamics of cancer proliferation in single-cell clones with SPRINTER. Image Credit: Anusorn Nakdee/Shutterstock.com In a recent study published in Nature ...
The artificial intelligence (AI) revolution continues to tout developing drugs faster and at lower cost, but are we there yet? On October 2nd, the FDA cleared an investigational new drug (IND) ...
Immatics has vaulted into phase 3 on the strength of early-stage data. The biotech is gearing up to start a pivotal trial of its melanoma cell therapy IMA203 this year in light of the response and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results